William Blair upgraded Biodesix (BDSX) to Outperform from Market Perform without a price target following the Q4 report. The company’s 2026 revenue guidance is 3% ahead of expectations and it disclosed a “significantly improved” balance sheet, the analyst tells investors in a research note. The firm says Biodesix has executed above target for three straight quarters and enters 2026 with momentum.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BDSX:
- Biodesix sees FY26 revenue $106M-$112M, consensus $105.9M
- Biodesix reports Q4 EPS (49c) vs. ($1.13) last year
- Biodesix: Strengthening Fundamentals, Emerging Profitability, and Strategic Growth Support Buy Rating and $20 Price Target
- Biodesix: Strong Operational Momentum but Ongoing Capital Concerns Justify Hold Rating
- Biodesix trading resumes